Insulin and cancer risk
Pro Research Analysisby 
Searched over 200M research papers
Insulin Therapy and Cancer Risk
Large-scale studies comparing different types of insulin therapy, such as insulin glargine, insulin detemir, and human insulin, have found no consistent evidence that using these insulins increases the risk of developing cancer over more than five years of follow-up. While a few associations were observed for specific cancers in certain subgroups, these findings were not consistent or sustained across all cancer types or durations of insulin use. Overall, the risk of cancer did not differ significantly between users of insulin analogues and those using human insulin 16. Specifically for breast cancer, meta-analyses and systematic reviews have shown no significant increase in risk for diabetic patients treated with insulin compared to those on non-insulin therapies 46. However, some studies note methodological limitations and short follow-up periods, leaving some uncertainty, particularly regarding breast cancer .
Insulin Resistance, Hyperinsulinemia, and Cancer Risk
Insulin resistance, which leads to higher circulating insulin levels (hyperinsulinemia), is a key factor linking obesity, type 2 diabetes, and increased cancer risk. Multiple studies have shown that insulin resistance and hyperinsulinemia are associated with a higher risk of several cancers, especially those of the colon, liver, pancreas, and, to a lesser extent, breast and prostate 2378+2 MORE. The mechanisms involve insulin’s ability to promote cell growth and proliferation, as well as chronic inflammation and increased levels of insulin-like growth factor 1 (IGF-1), which can further stimulate tumor development 2378+2 MORE.
Biological Mechanisms: Insulin, IGF-1, and Tumor Growth
Insulin acts as both a metabolic regulator and a growth factor. In cancer cells, insulin receptors—especially the A isoform—are often overexpressed, making these cells more responsive to insulin’s growth-promoting effects. This selective advantage can lead to increased tumor growth in the presence of high insulin levels 910. Additionally, the insulin/IGF-1 axis is implicated in cancer progression, with elevated IGF-1 levels linked to a slightly increased risk of some cancers 5710. Chronic hyperinsulinemia and the resulting increase in bioavailable IGF-1 can stimulate tumor growth and may also contribute to resistance to certain cancer therapies 710.
Impact of Metabolic Disorders on Cancer Outcomes
Patients with metabolic disorders such as obesity, insulin resistance, and type 2 diabetes not only have a higher risk of developing cancer but also tend to have poorer cancer treatment outcomes, including higher recurrence rates and reduced overall survival 237. Lifestyle factors that reduce insulin resistance, such as increased physical activity and possibly coffee consumption, have been associated with lower risks of certain cancers .
Conclusion
Current evidence suggests that while insulin therapy itself does not consistently increase cancer risk, conditions characterized by insulin resistance and hyperinsulinemia—such as obesity and type 2 diabetes—are clearly linked to a higher risk of several cancers. The biological mechanisms involve both direct effects of insulin and IGF-1 on cell growth and indirect effects through chronic inflammation. Managing insulin resistance through lifestyle interventions may help reduce cancer risk and improve outcomes for those with metabolic disorders.
Sources and full results
Most relevant research papers on this topic